489
Participants
Start Date
December 11, 2014
Primary Completion Date
March 31, 2019
Study Completion Date
March 31, 2019
Any FDA approved antipsychotic agent
Investigators are free to choose the most appropriate treatment for their clients
aripiprazole long acting injectable formulation
Carolina Behavioral Care, Durham
Grady Memorial Hospital, Atlanta
Augusta University, Augusta
U. of Florida College of Medicine, Jacksonville
Apalachee Center, Inc., Tallahassee
Meridian Behavioral Healthcare, Gainesville
Henderson Behavioral Health, Fort Lauderdale
Jerome Golden Center for Behavioral Health, West Palm Beach
Suncoast Center, St. Petersburg
LifeStream Behavioral Center, Leesburg
Carey Counseling Center, Huntingdon
The Counseling Center of Wayne and Holmes Counties, Wooster
Central Community Health Board of Hamilton Co., Cincinnati
University of Michigan, Ann Arbor
Early Treatment and Cognitive Health, East Lansing
Community Mental Health for Central Michigan, Mount Pleasant
WMU School of Medicine, Kalamazoo
Muskegon County Community Mental Health, Muskegon
Cherry Street Health Services, Grand Rapids
University of Iowa Psychiatry Research, Iowa City
Northwestern University Feinberg School of Medicine, Chicago
Chestnut Health Systems, Granite City
Saint Louis University CRU, St Louis
PsychCare Consultants Research, St Louis
Creighton University, Omaha
MHC Community Healthcore, Longview
Baylor College of Medicine, Houston
Spindletop Center, Beaumont
The Center for Health Care Services, San Antonio
Psychiatric & Behavioral Solutions, Salt Lake City
La Frontera, Tucson
San Fernando Mental Health Center, Granada Hills
Stanford School of Medicine, Palo Alto
PeaceHealth Medical Group, Eugene
Corrigan Mental Health Center, Fall River
U. Mass Medical School, Worcester
The Mental Health Center of Greater Manchester, Manchester
Healthy Perspectives, Nashua
New Bridge Medical Center, Paramus
Collaborators (1)
Otsuka America Pharmaceutical
INDUSTRY
Vanguard Research Group
OTHER